Most Read Articles
Jairia Dela Cruz, 26 Jun 2018
The monoclonal antibody denosumab is safe and effective for use in patients on glucocorticoids and at risk of developing fractures, with a recent study showing that the drug performs better than risedronate in increasing bone mineral density (BMD).
Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Stephen Padilla, 20 Sep 2018
Romosozumab therapy for 12 months is well tolerated and effective in increasing spine and hip bone mineral density (BMD) in men with osteoporosis, according to a recent study.

Statin use may lower risks of osteoporosis, fracture in stroke patients

11 Oct 2018

Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.

Poststroke statin use correlated with a decreased overall risk of the primary outcome of osteoporosis, hip fractures and vertebral fracture (adjusted hazard ratio [aHR], 0.66; p<0.001). Subanalyses revealed a correlation between statin use and a lower risk of all individual outcomes, including osteoporosis (aHR, 0.68; p<0.001), hip fracture (aHR, 0.59; p<0.001) and vertebral fracture (aHR, 0.73; p=0.003).

There was a dose-effect relationship between the outcomes and statin use. The aHRs for developing the primary outcome were 0.96 for patients who used 1–90 cumulative defined daily doses of statins, 0.86 for 91–365 and 0.34 for >365. These dose-effect relationships persisted in subgroup analyses stratified by age, sex and stroke type and sensitivity analyses conducted without propensity score matching.

This population-based propensity score-matched cohort study examined the association between statin use and risks of osteoporosis and fracture in stroke patients using Taiwan’s National Health Insurance Research Database.

The authors identified patients newly diagnosed with a stroke between 2000 and 2012. A total of 5,254 patients were included after propensity-score matching. Cox proportional hazards regression models according to statin use status were generated to calculate HRs for poststroke osteoporosis, hip fracture and vertebral fracture.

“Poststroke osteoporosis and consequent fractures increase the risk of morbidity and mortality and cause considerable socioeconomic burden,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 26 Jun 2018
The monoclonal antibody denosumab is safe and effective for use in patients on glucocorticoids and at risk of developing fractures, with a recent study showing that the drug performs better than risedronate in increasing bone mineral density (BMD).
Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Stephen Padilla, 20 Sep 2018
Romosozumab therapy for 12 months is well tolerated and effective in increasing spine and hip bone mineral density (BMD) in men with osteoporosis, according to a recent study.